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In a  preceding paper (1) it was shown that protection against the lethal ef- 
fects of intravenously injected virulent mycobacteria in mice is related to the 
vaccinal population which develops within an animal's tissue. 
Living Calmette-Gu6rin bacillus (BCG) is also capable of inducing significant 
antitubercular protection against respiratori]y induced tuberculosis (2,  3).  But 
few attempts have been made to correlate the size of the vaccinal population 
in vivo with the  evolution of the immune  state. 
In the  experiments  to  be described herein,  mice were  immunized  with  the 
Montreal strain of BCG. After vaccination, they were superinfected with viru- 
lent human  bacilli administered by the  aerosol route,  At sequential intervals 
thereafter  the numbers  of vaccinal or of challenge bacilli present  in  lungs  or 
spleens were determined. The extent of retardation of the growth of challenge 
bacilli was used as a  measure of immune resistance. 
A slight degree of protection was found in the lungs and splanchnic tissues of 
vaccinated animals. This heightened  resistance  appeared only after extensive 
multiplication of  the  vaccine had  occurred,  resulting  in  the  accumulation  of 
large numbers  of BCG bacilli in the animal's tissues. 
Materials and Methods 
The materials and methods used in this study have been described (1, 4). 4-6 wk old  female 
mice were used.  They were  maintained on  a  commercial  diet  (D  & G pellets, Dietrich & 
Gambrill Inc., Fredrick, Md.) fed ad libitum. 
The H37Rv strain of Mycobacterium tuberculosis obtained from The Trudeau Foundation 
Laboratory, Saranac Lake, N.Y. was cultured in Kirchner's medium  containing Tween 80 
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and bovine serum albumin. The Montreal strain of BCG was obtained from the Institute de 
Microbiologie et  d'Hygiene  de  l'Universit6 de  Montr6al,  Montreal,  Canada  through the 
courtesy of Dr. Frappier. 1 This strain was supplied as a standardized, commercially available, 
lyophilized culture containing  112  mg  of  bacillary material per vial; it was  used  as  such 
without subculturing. 
Respiratory Infectlon.--Suspensions  for  nebulization were  prepared  as  follows.  Recon- 
stituted suspensions of lyophillzed BC G or of young growing H37Rv cultures were homogenized 
with a Teflon glass homogenizer and filtered through a  membrane filter (Millipore Corpora- 
tion, Bedford,  Mass.)  of  5 /z pore  size to provide a  suspension containing predominantly 
single bacilli. Filtered suspensions were stored at  -60°C  until use. Mice were infected in a 
Middlebrook-type  aerosol  infection  chamber  (Tri-R  Instrument  Corporation,  Rockville 
Centre, N.Y.). Infective aerosols were obtained by nebulizing 10 ml of suspension containing 
approximately 1 X  106 viable units of mycobacteria per ml over a 60 min period. 
Enumeration  of Mycobacteria in  Organs.--At  intervals  after  vaccination  or  challenge, 
mice were  sacrificed and  their lungs and  spleens were  homogenized in Teflon glass tissue 
grinders containing 5  ml of 2% albumin water.  Samples of homogenate were diluted with 
distilled water containing 0.01% bovine serum albumin. Suitable portions were pipetted into 
sterile screw cap tubes and to each tube was added 2 ml of soft agar medium (4). Incubation 
was at 37°C for 21 days. The number of viable mycobacteria was estimated from the number 
of colonies obtained. 
The organisms derived from the challenge dose were distinguished from BCG bacilli by 
the differential inhibitor 2-thiophenecarboxylic acid hydrazide. The inhibitor, in water, was 
sterilized by filtration and added to the soft agar medium in a final concentration of 15/zg/ml. 
RESULTS 
Growth of BCG in Organs of Mice After Aerosol Vaccination.--Vaccination 
was readily accomplished by aerosol administration of BCG. 
The in vivo growth of the Montreal strain of BCG given in this manner was followed in the 
first experiment. 6-wk old female mice were placed in the infection basket of the aerosol appara- 
tus. They were infected by exposure to the aerosol obtained by nebulization of a 10 ml suspen- 
sion containing 105`5 viable units of BCG per ml for 60 rain. The mice were then randomly 
recaged in groups of five. At intervals of time after infection a group of mice was sacrificed and 
the numbers of organisms present in the lungs and spleens determined. The results of this ex- 
periment are detailed in Table I. 
As seen in Table I, BCG bacilli could be detected in the lung immediately 
after aerosol infection and increased in numbers for 4-6 wk thereafter. Mter 
reaching  this maximum  the numbers  steadily declined  and 20-40 wk  after in- 
fection mycobacteria were present in lungs of occasional animals only. 
BCG  organisms  consistently appeared  in the spleens  of vaccinated  animals 
5  or 6 wk after aerosol infection. The numbers of organisms recovered from the 
animals'  spleens  declined  slightly  after  10  wk.  In  contrast  to  the findings in 
pulmonary  tissue,  however,  BCG  organisms  persisted  in  the  animals'  spleens 
for long periods of time. 
1 The authors are indebted to Dr. Frappier of the Institute of Hygiene for making large 
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The growth of several other strains of BCG in the organs of mice after aerosol 
vaccination was  tested  in subsequent experiments. These results will be  de- 
scribed in detail elsewhere.  2 It may be noted, however, that the in vivo growth 
of  other  strains of  BCG  differed  from  that  of  the  Montreal strain.  Phipps 
strain bacilli multiplied as extensively in pulmonary tissue as did the Montreal 
strain; however,  they declined more rapidly in the  lungs than did  bacilli of 
the Montreal strain. Other strains of BCG showed less or no ability to grow in 
pulmonary tissue. These differences are similar to those reported by other in- 
vestigators for BCG substrains intravenously  injected into mice (5-7). 
TABLE I 
BCG Organisms in Organs of Mice after Aerosol Vaccination 
No. of BCG organisms  recovered from organs at indicated  time after infection* 
Time after infection 
Lung  Spleen 
wk  log  SD  log  SO 
0  1.6~  4-0.3  0  -- 
2  2.7  4-0.9  0  -- 
3  4.1  4-1.2  0  -- 
4  5.2  4-0.8  0  -- 
6  5.8  4-0.3  2.4  4-0.6 
10  5.0  ::t:0.7  2.5  4-0.8 
* Numbers  of BCG organisms (expressed as logs) recovered from organs of mice after 
aerosol vaccination 4- standard  deviation. Infection was produced by nebulization of 10 ml 
of suspension containing 105~ BCG bacilli per ml over a 60 min period. 
Average of five mice. Values indicate number of bacilli present in entire tissue homog- 
enate. 
Effect of BCG Vaccination on the In Vivo Growth of Virulent Human Bacilli.- 
The numbers of virulent bacilli recovered from organs of BCG-vaccinated mice 
at intervals after infection is described in the next experiment. 
Female mice were vaccinated with living BCG as in the previous experiment. 10 wk after 
vaccination these, along with comparable untreated animals, were superinfected by aerosol 
exposure to virulent human bacilli. 10 ml of suspension containing 105.8 viable virulent bacilli 
per ml were nebulized for 60 rain. Animals were sacrificed at intervals after infection, their 
lungs and spleens were removed and homogenized. Dilutions of the homogenate were plated in 
medium containing 2-thiophenecarboxylic acid hydrazide which prevents the growth of BCG 
(Table II). 
Virulent mycobacteria initially grew at the same rate in lungs of control and 
of vaccinated mice. 4  wk after challenge, however,  significantly fewer  bacilli 
were recovered from lungs of vaccinated mice than from normal animals. The 
difference between the  two groups diminished with  time and eventually dis- 
appeared. 
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Virulent organisms were not obtained from spleens of mice until 4  wk after 
challenge, that  is,  at  the  height  of  the  pulmonary infection. The  growth  of 
virulent organisms in the spleens of vaccinated animals was greatly retarded. 
10 wk after infection, however,  similar numbers of organisms were recovered 
from the spleens in either group. 
Route  of Vaccination.--Study  was made of the relative effectiveness of  im- 
munization achieved in animals given BCG by different routes of administra- 
tion.  It  was  found  that  successful immunization could  be  achieved  by  the 
intravenous or intraperitoneal route as well as by aerosol vaccination. 
TABLE II 
Growth of Virulent  Human  Bacilli  in Organs of BCG-Vaecinated 
and Unvaccinated Mice 
No. of virulent bacilli  present in organ at indicated time* 
Time 
after  Lung  Spleen 
infection 
Control  Vaccinatedkt  Control  Vaccinat  ed:~ 
wk  log  so  log  so  log  SD  log  SD 
2  4.7§  4-0.6  4.1  4-0.5  0  --  0  -- 
4  7.0  4-0.8  5.611  4-0.5  4.0  4-0.7  2.1[[  4-0.7 
6  6.0  4-1.0  6.0  4-0.8  4.6  4-0.6  2.611  4-0.7 
10  6.4  4-0.5  5.8  4-0.7  4.6  4-0.5  4.0  4-1.0 
* Numbers  of  human bacilli  (expressed as  logs) recovered from  organs of  mice after 
aerosol infection 4- standard deviation. Infection was produced by nebulization of 10 ml of 
suspension containing 105.8 H37Rv bacilli per ml over a 60 rain period. 
:~ Animals were vaccinated by aerosol exposure to Montreal strain BCG (10 ml containing 
105.5 viable BCG bacilli per ml for 60 rain) 10 wk before virulent challenge infection. 
§ Average of five mice. Values are for 1 ml of tissue homogenate (out of a total of 5 ml). 
II Indicates values significantly different (P  =  <  0.05) from those of comparable control 
mice. 
In a typical experiment 5-wk old mice were given BCG by different routes. One group of 
animals was exposed to an aerosol obtained by nebulizing 10 ml of suspension containing 105.  5 
viable units BCG per ml over a 60-min period. A second group of mice received 104'18 viable 
units of BCG by peritoneal injection. Still another group was given 103.1  s viable units of BCG 
by the intravenous route. 
5 wk after vaccination, representative animals from each group, along with untreated con- 
trol mice, were challenged with virulent organisms given by the respiratory route. The condi- 
tions of the challenge infection were similar to those previously described. 
The number of BCG organisms present in animals' spleens and lungs were 
determined at various intervals after vaccination. In animals exposed to nebu- 
lized vaccine, extensive multiplication of BCG occurred initially in the lungs. 
BCG administered by the peritoneal route was immediately taken up by both 
spleens and lungs. Little multiplication of BCG occurred in either organ, how- 
ever. BCG organisms rapidly appeared in both spleens and lungs after intra- 
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The  number  of  BCG  organisms present  in  the  various  organs  5  wk  after 
vaccination is given in Table III. As may be seen in the Table, large numbers of 
BCG were present in either spleen or lung by the time of challenge infection 
irrespective of the initial route of vaccination. 
4  wk after challenge infection, the number of virulent bacilli present in the 
lungs and spleens of vaccinated and control animals was determined. As shown 
in Table III, the number of challenge organisms present in pulmonary tissue 
at this time were significantly lower in all the vaccinated animals. The degree 
of depression of growth in pulmonary tissue was relatively similar in all cases. 
TABLE III 
Virulent Bacilli Recovered  from Organs of Mice Vaccinated by Three Routes 
Route of 
vaccine* 
BCG present at 
time of challenge~: 
No. of virulent bacilli  present in organs 
4 wk after virulent infection:~, § 
Lung  Spleen  Lung  Spleen 
log  log  log  SD  log  SD 
Control  --  --  5.9  4-0.37  2.4  4-0.31 
Aerosol  5.4  0.1  4.611  ±0.39  1.8  4-0.95 
Intravenous  3.1  4.3  4.7 ][  ±0.33  1. 311  4-0.71 
Intraperit  oneal  2.5  1.5  4.31]  4-0.69  1.9  4-0.44 
* Animals were vaccinated by aerosol exposure to Montreal strain BCG (10 ml contain- 
ing 105.5 viable BCG bacilli per ml for 60 min), intravenous injection of 10  aas BCG bacilli, 
or intraperitoneal injection of 104"18 BCG bacilli. 
:~ Animals were challenged  by exposure  to virulent aerosol challenge  (10 ml containing 
105.8 H37Rv bacilli per ml for 60 min) 5 wk after vaccination. 
§ Average of five mice  in each case. Values are for 1 ml of tissue homogenate  (out of a 
total of 5  ml). 
[] Indicates values significantly different  (P  =  <  0.05) from those of comparable control 
mice. 
Thus,  the route of administration of vaccine appeared to have relatively little 
influence on the development of immunity by pulmonary tissue. 
The number of challenge bacilli recovered from splenic tissue was also lower 
in vaccinated animals than in unvaccinated animals, although only in animals 
vaccinated by the  intravenous  route  were  these differences of statistical sig- 
nificance. 
Effect of Vaccine Dose.--The  relation between the quantity of BCG admin- 
istered to animals and the antituberculous resistance attained by their tissues 
was studied in several experiments. 
The procedures were similar to those described in the preceding experiments.  Female ani- 
mals were used. In the experiment illustrated in Table IV, they were 5 wk old when vaccinated. 
Each group of animals was vaccinated with a serially diluted suspension of fleshly reconsti- 
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untreated control  animals, were challenged by respiratory  infection with virulent human 
bacilli. They were sacrificed 4 wk after challenge infection and the number of virulent bacilli 
present in their organs determined. 
The number of BCG organisms administered to the mice and the vaccinal 
population present in the animals' organs 6 wk after vaccination are indicated 
in the first columns of Table IV. As in preceding experiments, the  organs of 
animals receiving the largest intraperitoneal dose of BCG contained the largest 
TABLE IV 
Virulent  Bacilli  Recovered from  Organs of Intraperitoneally  Vaccinated  Mice  at  Indicated 
Intervals  after  Infection 
Organ 
No. of  No. of vaccine  BCG 
injected  organisms 
(viable units)  present in tissue* 
No. of virulent bacilli  recovered at indicated 
time after challenge  infections 
2 wk  4 wk  6 wk 
Lung 
Spleen 
log 
0 
150  0 
1.5  X  104  1.7  4- 
1.5  X  10 s  3.7  ± 
0 
150  3.0  4- 
1.5  X  104  5.5  -4- 
1.5  X  l0  s  5.2  4- 
log  sD  log  SD  log  SD 
4.3  ,4-0.23  7.4  4-0.91  6.2  ,4.1.15 
4.2  4-0.38  6.4  4-1.33  6.0  4-0.85 
0.8  4.3  4-0.28  5.1§  4-0.91  6.1  4-0.80 
2.3  4.1  4-0.41  5.2§  ,4.0.91  6.7  4-0.60 
0  --  3.5  4-1.28  4.7  4-0.38 
0.7  0  --  2.7  4-0.28  4.0  :t:0.92 
1.0  0  --  2.2§  4-0.28  3.5§  ±0.69 
1.0  0  --  2.4§  4-0.42  3.4§  4-0.69 
* Number of BCG organisms (expressed in logs) recovered from tissue 6 wk after  vac- 
cination ±  standard deviation. Average of five mice. All values are for 1 ml of tissue homoge- 
nate (out of a total of 5 ml). 
* Time between vaccination  and challenge was  5 wk.  Virulent  challenge consisted of 
exposure to an aerosol produced by nebulizing 10 ml of suspension containing 10 ~'s H37Rv 
per ml for 60 min. 
§ Indicates values significantly different (P =  <  0.05) from those of comparable control 
mice. 
numbers of vaccine organisms. Both lungs and spleens of these animals were 
resistant to  the  growth  of  virulent bacilli. Mice  receiving the  next  smaller 
quantity of  vaccine had  a  less  extensive BCG  infestation. Organs  of  these 
mice, however, were also resistant to virulent  bacilli. Mice receiving the smallest 
quantity of BCG showed only a  slight vaccinal infection and this was almost 
entirely limited to splanchnic tissue. They were significantly less resistant to 
challenge infection. 
It should be noted, however, that the degree of resistance attained by ani- 
mals was not directly related to the size of the vaccinal population within their 
organs. Thus, the number of challenge organisms present in organs of mice given 
the highest quantity of BCG were no lower than those recovered from organs 
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Similar results have been obtained in other experiments. When small quanti- 
ties of BCG were administered by the peritoneal route,  the animals often en- 
tirely failed to  develop pulmonary immunity. After  administration of  larger 
quantities  of  vaccine,  they  regularly  developed  resistance.  The  degree  of 
resistance, as measured by the numbers of virulent bacilli in pulmonary tissue 
4  wk after challenge infection, was largely the same irrespective of the size of 
the vaccinating dose. 
TABLE V 
Number of l'ir~dent Mycobacteria in Organs of Mice at Different Times After Vaccination 
Time 
after 
vacci- 
nation* 
wk 
1 
2 
3 
4 
5 
6 
10 
20 
No. of BCGbacilli present 
in organs at given time 
after vaccination 
No. of virulent bacilli recovered from 
organs 4  wk after challenge:~ 
log 
0.s§ 
1.2 
3.0 
5.1 
5.4 
6.2 
3.1 
1.6 
Lung  Spleen 
Lung  Spleen  Control  Vaccination 
log  so 
0  --- 
0  --- 
0  --- 
0 
0.1  +0.05 
1.1  4-1.34 
3.O  4-0.12 
3.0  ±0.28 
log  SD 
6.8  4-0.57 
6.5  4-0.17 
5.9  -4-0.37 
5.7  4-0.82 
log 
7.3 
6.0 
4~611 
4All 
SD 
4-0.65 
4-0.25 I 
+0.39j 
+0.69 
log  sn 
4.2  +0.17i 
3.8  4-0.33 
2.4  -4-0.31 
3.4  4-0.36 
Control  Vaccination 
log  SD 
4.2  4-0.70 
3.0  4-0.6O 
1.8  ~0.95 
2.411  4-0.30 
sn 
-4-0.211 
+0.35 
4-0.76 
4-0.27 
±0.56 
+0.27 
+0.25 
4-1.15 
* Animals were vaccinated  by aerosol exposure to  10 ml containing  105.5 viable BCG 
bacilli per ml nebulized for 60 rain. 
Virulent challenge occurred at indicated times after vaccination. Infection was produced 
by nebulization of 10 ml containing 105's H37Rv per ml for 60 rain. Animals were sacrificed 
4 wk later; figures indicate the number of organisms recovered from their organs. 
§ Average of five mice. Values are for 1 ml of tissue homogenate (out of a total of 5 ml). 
][ Indicates values significantly different (P  =  <  0.05) from those of comparable control 
mice. 
Rate of Appearance of Acquired Resistance.-In the next experiment mice were again vacci- 
nated by exposure to nebulized BCG. At intervals  thereafter  they were sacrificed and the 
vaccinal populations in their tissues ascertained. At intervals of times, groups of animals, along 
with comparable nonvaccinated mice, were challenged with virulent bacilli by the respiratory 
route. The relative resistance was assessed by determining the numbers of virulent organisms 
present in lung and spleen 4 wk after challenge.  The results are shown in Table V. 
As may be seen, the appearance of immunity  was closely related to the phase 
of development of the vaccinating process. Increasing numbers of BCG bacilli 
were recovered 4 wk after aerosol vaccination. No heightened resistance could 
be detected,  however,  until the 5th wk after BCG administration when vac- 
cinated animals appeared to be able to retard the pulmonary growth of chal- 
lenge bacilli. No retardation of growth,  however, was found in the spleens of TAKATERU  IZUMI  AND  RICHARD  COSTELLO  383 
immunized  mice.  6  wk  after vaccination BCG  organisms were  first recovered 
from  the  splenic  tissue  of  treated  animals;  in  animals  challenged  after  this 
period,  an  increased  antitubercular  resistance  of  both  splenic  and pulmonary 
tissue was found. 
Duration  of Immunity in  Vaccinated Mice.--The  persistence  of  pulmonary 
immunity  in BCG-vaccinated  animals was determined in the next experiment. 
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Fro.  1. Number of virulent human bacilli in organ of control and vaccinated mice. Bars 
refer to organisms recovered from five individual animals 4 wk after aerosol challenge with 
10 ml of suspension containing 105. s viable H37Rv per ml, nebulized for 60 min. Animals were 
vaccinated with BCG 1 wk (i.v.) or 1 yr (aerosol and i.p.) before challenge. Number of BCG 
organisms present in organs of these latter animals is also indicated in figure. 
Several litters of day old mice were obtained and the babies were randomly mixed. One 
group of baby animals was vaccinated by aerosol infection with BCG. The newborn animals 
were placed in the infection basket and 10 ml of suspension containing 105.5 viable BCG were 
nebulized over a 60 rain period. A second group of babies were intraperitoneally injected  3 with 
a Intraperitoneal injection of baby mice was accomplished by the following technique. The 
animal was inverted and held with its tail away from the operator. A  1/4 ml syringe with a 
30 gauge 3/4 inch needle was used. Subcutaneous entry was made at the level of the upper 
vertebrate. The needle was directed towards the sternum, being carefully kept between the 
animal's skin and its rib cage.  When the diaphram was reached the needle was depressed 
slightly, puncture of the diaphram made, and the peritoneal cavity entered. After injection of 
the inoculum  the needle was  slowly withdrawn. 384  DEVELOPMENT  OF  PULMONARY  TUBERCULOSIS  RESISTANCE 
0.05 ml of a suspension of vaccine containing 106.2 organisms. In both cases, animals were re- 
turned to randomly selected foster mothers after vaccination. 8 animals were placed with each 
nursing female. At 21 days of age theywere weaned, segregated bysex, and recagedingroups of 
20 animals. All animals, including untreated control mice, were maintained without further 
treatment for the subsequent year. 
At this time one half of the untreated animals were given an intravenous injection of 106.2 
viable units of BCG. The following wk animals from each vaccinated group, along with the re- 
maining untreated control mice, were challenged by superinfection with virulent human bacilli 
administered by the respiratory route. At the same time the numbers of BCG present in lungs 
and spleens of animals vaccinated the preceding year were ascertained. 4 wk after challenge 
infection, all animals were sacrificed and the number of virulent bacilli present in their lungs 
and spleens determined. The results are given below and in Fig. 1. 
All  vaccinated  animals  were  significantly  protected  against  challenge  in- 
fection.  Moreover,  the  degree  of  protection  was  approximately  the  same  in 
each  case.  Thus,  tissues of  animals having  received vaccine a  year previously 
were  as  able to retard  the growth  of virulent bacilli as organs  of animals vac- 
cinated  1 wk before challenge. 
As seen in Fig.  1,  organs of animals vaccinated  the preceding year still con- 
tained  significant quantities of vaccinal organisms at the time of challenge in- 
fection.  The  numbers  of BCG  were  approximately  the same  in organs  in  ani- 
mals vaccinated  by  either the peritoneal  or respiratory route. 
Histological Observations.--The histological development of pulmonary lesions 
was followed  in several of the experiments described  above. 
Animals were sacrificed at intervals after respiratory vaccination or challenge infection. 
Gross observation of pulmonary tissue was made in situ. Tissues were subsequently fixed in 
10% formalin and sections stained with hematoxylin and eosin or with Ziehl-Neelsen acid fast 
stain. 
The  typical  pulmonary  lesion  in  animals  challenged with  virulent  bacilli  was  a  well 
defined granulomatous process as described by other investigators. Lesions were well organized 
and consisted primarily of epithelioid cells and lymphocytes. Giant cells and foam cells were 
rare. Caseation necrosis did not occur. Acid fast bacilli were rare within the organized lesions. 
Similar lesions occurred in vaccinated animals. Visible lesions occurred  at generally the 
same time in vaccinated or control animals. No significant difference in numbers of lesions were 
found in animals of the two groups. Lesions in vaccinated animals were not appreciably smaller 
than in untreated mice. 
On the other hand, animals vaccinated with BCG by aerosol but not challenged with viru- 
lent organisms also developed pulmonary lesions within 6 wk after vaccination. By 10 wk after 
vaccination, lesions attained a size of 1-2 mm and became slightly larger, reaching a maximum 
size by the 12th wk. Beyond this period the size of the lesion slowly decreased. Appreciable 
resolution occurred by the 4th month. The BCG lesions had largely healed by the 6th-9th 
month after infection. 
Similar lesions appeared in mice given aerosol vaccination with Phipps organisms. Only 
small lesions, if any, occurred in animals vaccinated with other strains of BCG. 
On microscopic observation the BCG lesions were characteristic of a well organized granu- 
lomatous process. The lung showed striking lymphoid infiltration of perivascular areas.  Le- 
sions consisted of epithelioid cells and large numbers of deeply staining lymphoid ceils.  Few 
giant or  foam cells were present.  No  necrosis  occurred.  Extremely  few  BCG  bacilli were TAKATERU  IZUMI  AND  RICHARD  COSTELLO  385 
found. Undamaged  parenchymal tissue of the animals appeared to have an increased cellu- 
larity; many of the additional cells were structurally compatible with mononuclear phago- 
cytic cells. 
DISCUSSION 
Mice vaccinated with living BCG are significantly more resistant to respira- 
tory infection than  are  unvaccinated  control mice. Larson  and  Wicht  have 
reported that the appearance of grossly visible pulmonary lesions in animals 
challenged with virulent mycobacteria by the respiratory route is greatly re- 
tarded in mice vaccinated with large doses of H37Ra, BCG, or atypical myco- 
bacteria by the  intravenous or respiratory route  (2,  8).  These investigators 
also noted that the numbers of mycobacteria present in the lungs of vaccinated 
animals were significantly lower than in control mice. Ribi et al. confirmed these 
findings,  adding  that  significant  pulmonary  protection,  greater  than  that 
obtained with living BCG, was  also achieved by intravenous injection of oil 
in water emulsions of mycobacterial cell walls (9,  10).  Smith et al. found little 
difference in the response of BCG-vaccinated and unvaccinated mice to viru- 
lent human  respiratory infection,  although  the  numbers  of bacilli recovered 
from lungs and spleens in immunized mice were smaller at certain intervals of 
time after infection (11). 
In the experiments described here, successful vaccination was attained after 
aerosol exposure of mice to BCG as well as by intravenous or intraperitoneal 
injection of the vaccine. 
BCG organisms multiplied extensively in pulmonary tissue after inhalation. 
Growth of the vaccine in the lung continued unabated  until 6 wk after ex- 
posure. After this time, the numbers of BCG bacilli in the animals' lungs de- 
clined. At this same time, BCG organisms were first recovered from spleens. 
Vaccinal multiplication  continued  in  this  organ for several wk,  after which 
time the numbers of BCG slightly declined, persisting at these values there- 
after. 
The development of immune resistance was closely related to the multipli- 
cation of the vaccinal bacilli. Thus, animals first became resistant to the growth 
of virulent challenge bacilli when the BCG population in pulmonary tissues 
had reached its height and had begun to decline. Similarly, splenic tissue did 
not become consistently resistant to the human organisms until the animals' 
spleens contained large numbers of vaccinal organisms. 
It is worth noting that the development of pulmonary resistance was also 
correlated with the appearance of significant histological changes in the lungs 
of  BCG-vaccinated  mice.  6-10  wk  after  aerosol vaccination  lungs  of  mice 
developed a  significant  granulomatous  reaction  characterized by large  infil- 
trations of macrophages and other lymphoid cells.  At the same time, animals 
first demonstrated pulmonary resistance to challenge infection. 
The development of discrete macroscopic lesions in lungs of mice infected 
with  certain strains  of BCG has  been noted by others  (12),  although  their 386  DEVELOPMENT  OF  PULMONARY  TUBERCULOSIS  RESISTANCE 
occurrence has rarely been considered in studies concerned with antitubercular 
immunity. Youmans and Youmans (13) and Barclay et al. (14) have described 
in  detail  the  granulomatous  response  developing  in  mice  after  intravenous 
injection of living or dead mycobacterial cells.  Both  groups  of investigators 
noted a correlation between the magnitude of the macrophage response and the 
degree of resistance against virulent challenge. 
At least two lines of evidence reported in this paper tend to speak against a 
simple correlation between pulmonary resistance to challenge organisms and 
the occurrence of granulomatous pulmonary tissue. First, growth of challenge 
bacilli was  not  immediately depressed in  the  lungs of vaccinated animals  as 
it would be if the inhibitory response was due solely to the presence of an inimi- 
cal  tissue  environment.  In  fact,  organisms  grew  at  the  same  rate  in  either 
vaccinated or unvaccinated animals for 2 wk after infection and only during 
the following fortnight was  their growth  severely depressed.  Secondly, mice 
vaccinated  by  intraperitoneal  administration  of  BCG  developed  as  large  a 
degree of resistance as animals vaccinated by the intravenous or respiratory 
route. Relatively few BCG bacilli reached pulmonary parenchyma following 
intraperitoneal injection of vaccine. Moreover, gross pulmonary lesions rarely 
developed in mice given vaccine by this route. 
It is of interest to compare the ability of mice to repress virulent mycobacteria 
administered by the respiratory route with the protection attained against the 
lethal  effects of  infection  such  as  that  described  in  the  preceding  paper. 
Resistance of pulmonary tissue developed only several wk after respiratory or 
peritoneal vaccination.  Mortality protection is much  more rapidly attained, 
at least within 7 days and perhaps within 3 (15). Protection against mortality 
is effective against a limited range of challenge doses and is readily overwhelmed 
(16). Resistance of pulmonary tissue is equally exerted against both heavy and 
light challenge infections (4). Both mortality and pulmonary resistance depend 
on the presence within the animal of a large population of vaccinal organisms. 
The degree  of  resistance  attained  against  mortality protection, however,  is 
related to the total quantity of vaccinal organisms present with the tissues, i.e. 
is dose dependent, whereas pulmonary resistance was present at relatively the 
same level in all successfully vaccinated animals. Mortality resistance is readily 
induced by either living or dead mycobacterial preparations;  pulmonary re- 
sistance is difficult to induce with dead mycobacteria, requiring relatively large 
quantities of vaccine administered by the intravenous route.  4 
SUMMARY 
The course of pulmonary tuberculosis  was  followed in  control and  BCG- 
vaccinated  mice.  Resistance  was  evaluated  by determining  the  numbers  of 
4 Costello, R., and T. Izumi. Data to be published. TAKATERU  IZUMI  AND  RICHARD  COSTELLO  387 
virulent  mycobacteria  recovered  from  the  organs  at  various  intervals  after 
airborn infection. 
A  limited  but significant retardation  of growth of challenge bacilli was ob- 
served in both pulmonary and splenic tissues of successfully vaccinated animals. 
This retardation was manifested chiefly during the early stages of the infection. 
However,  the  numbers  of virulent  organisms  recovered  from  the  organs  of 
either vaccinated or control animals were much the same at later stages of the 
infection. 
The appearance of pulmonary immunity was related to the stage of develop- 
ment in vivo of the vaccinal population. Only after large numbers of vaccinal 
bacilli could be recovered from the tissues was heightened resistance observed. 
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